Korea Arlico Pharm Co.,Ltd.

A260660

KR7260660006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
4,800 ^KRW	-0.10%		-1.84%	-15.79%

2023	Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding	CI
2023	Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding	CI

Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on October 6, 2021.

October 19, 2021

From October 6, 2021 to October 15, 2021, the company has repurchased 64,000 shares, representing 0.42% for KRW 496.14 million. With this, the company has completed the repurchase of 64,000 shares, representing 0.42% for KRW 496.14 million under the buyback announced on October 6, 2021.

Latest news about Korea Arlico Pharm Co.,Ltd.

Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding	10/11	CI
Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding	08/11	CI
Korea Arlico Pharm Co.,Ltd. announced that it has received KRW 10 billion in funding from Hanyang Securities Co., Ltd., Investment Arm, NH Hedge Co., Ltd., SUSUNG ASSET MANAGEMENT Co., Ltd., Infinity Investment Advisory Co.,Ltd., and other investors	18/22/18	CI
Korea Arlico Pharm Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from Hanyang Securities Co., Ltd., Investment Arm, NH Hedge Co., Ltd., SUSUNG ASSET MANAGEMENT Co., Ltd., Infinity Investment Advisory Co.,Ltd. and other investors	11/22/11	CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on October 6, 2021.	19/21/19	CI
Korea Arlico Pharm Co.,Ltd.'s Equity Buyback announced on October 6, 2021, has closed with 64,000 shares, representing 0.42% for KRW 496.14 million.	15/21/15	CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for 64,000 shares.	06/21/06	CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.	06/21/06	CI
An unknown buyer acquired 2.5% stake in Korea Arlico Pharm Co.,Ltd. from Hanggu Lee for KRW 3.5 billion.	29/20/29	CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on March 13, 2020.	25/20/25	CI
Korea Arlico Pharm Co.,Ltd.'s Equity Buyback announced on March 13, 2020, has closed with 102,400 shares, representing 1.07% for KRW 837.77 million.	23/20/23	CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for 102,040 shares.	13/20/13	CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.	13/20/13	CI
Korea Arlico Pharm Co.,Ltd.'s Equity Buyback announced on June 3, 2019, has expired.	02/19/02	CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on June 3, 2019.	03/19/03	CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for KRW 1,000 million worth of its shares.	03/19/03	CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.	03/19/03	CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on August 20, 2018.	22/19/22	CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on August 20, 2018.	22/19/22	CI
Tranche Update on Korea Arlico Pharm Co.,Ltd.'s Equity Buyback Plan announced on August 20, 2018.	22/19/22	CI
Korea Arlico Pharm. Co., Ltd.’s Equity Buyback announced on August 20, 2018 has expired with 87,968 shares, representing 0.92% for KRW 1,076.43 million.	19/19/19	CI
Korea Arlico Pharm Co.,Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.	20/18/20	CI
Korea Arlico Pharm Co.,Ltd. authorizes a Buyback Plan.	20/18/20	CI
Korea Arlico Pharm Co., Ltd. announced that it has received KRW 2.82 billion in funding from IBK Securities Co., Ltd.	13/18/13	CI
Korea Arlico Pharm Co., Ltd. announced that it expects to receive KRW 2.82 billion in funding from IBK Securities Co., Ltd.	12/18/12	CI

Chart Korea Arlico Pharm Co.,Ltd.

Duration

Period

More charts

Company Profile

KOREA ARLICO PHARM CO.,LTD. is a Korea-based company that mainly engaged in the manufacturing and sale of pharmaceuticals. The Company manufactures and sells circulation system drugs, digestion drugs, anti-inflammatory analgesic, other prescription drug for treating hypertension, hyperlipidemia, peptic ulcer, indigestion, osteoarthritis, pain, and dementia, among others. The Company distributes its products within the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KOREA ARLICO PHARM CO.,LTD.	-15.79%	53.39M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.77B
OTSUKA HOLDINGS CO., LTD.	+28.00%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+18.82%	14.34B
ZYDUS LIFESCIENCES LIMITED	+55.83%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.70%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B